LigularinineCAS# 90364-90-2 |
- Hastacine
Catalog No.:BCN2086
CAS No.:20361-77-7
- Platyphylline
Catalog No.:BCN2115
CAS No.:480-78-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 90364-90-2 | SDF | Download SDF |
PubChem ID | 253293 | Appearance | Powder |
Formula | C18H27NO5 | M.Wt | 337.41 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
SMILES | CC=C1CC(C(C(=O)OCC2CCN3C2C(CC3)OC1=O)(C)O)C | ||
Standard InChIKey | BTHCJHQOYFUIMG-UUILKARUSA-N | ||
Standard InChI | InChI=1S/C18H27NO5/c1-4-12-9-11(2)18(3,22)17(21)23-10-13-5-7-19-8-6-14(15(13)19)24-16(12)20/h4,11,13-15,22H,5-10H2,1-3H3/b12-4+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Targets | DNA/RNA Synthesis |
Ligularinine Dilution Calculator
Ligularinine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.9638 mL | 14.8188 mL | 29.6375 mL | 59.2751 mL | 74.0938 mL |
5 mM | 0.5928 mL | 2.9638 mL | 5.9275 mL | 11.855 mL | 14.8188 mL |
10 mM | 0.2964 mL | 1.4819 mL | 2.9638 mL | 5.9275 mL | 7.4094 mL |
50 mM | 0.0593 mL | 0.2964 mL | 0.5928 mL | 1.1855 mL | 1.4819 mL |
100 mM | 0.0296 mL | 0.1482 mL | 0.2964 mL | 0.5928 mL | 0.7409 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Pitolisant hydrochloride
Catalog No.:BCC1863
CAS No.:903576-44-3
- Bicalutamide
Catalog No.:BCC2481
CAS No.:90357-06-5
- 7-Xylosyltaxol B
Catalog No.:BCN7675
CAS No.:90352-19-5
- 10-O-Coumaroyl-10-O-deacetylasperuloside
Catalog No.:BCN7614
CAS No.:903519-82-4
- Seneciphyllinine
Catalog No.:BCN2132
CAS No.:90341-45-0
- Shizukolidol
Catalog No.:BCN4444
CAS No.:90332-92-6
- 7-Xylosyltaxol
Catalog No.:BCN5341
CAS No.:90332-66-4
- 7-Xylosyl-10-deacetyltaxol C
Catalog No.:BCN7663
CAS No.:90332-65-3
- 7-Xylosyl-10-deacetyltaxol B
Catalog No.:BCN7667
CAS No.:90332-64-2
- 10-Deacetyl-7-xylosyl paclitaxel
Catalog No.:BCN2947
CAS No.:90332-63-1
- FPA 124
Catalog No.:BCC7518
CAS No.:902779-59-3
- UBP 310
Catalog No.:BCC6052
CAS No.:902464-46-4
- Neoligularidine
Catalog No.:BCN2137
CAS No.:90364-91-3
- Ligularizine
Catalog No.:BCN2091
CAS No.:90364-92-4
- (-)-Indolactam V
Catalog No.:BCC7735
CAS No.:90365-57-4
- Bleomycin Sulfate
Catalog No.:BCC3694
CAS No.:9041-93-4
- Neochamaejasmine B
Catalog No.:BCN3130
CAS No.:90411-12-4
- Neochamaejasmine A
Catalog No.:BCN3129
CAS No.:90411-13-5
- NU 1025
Catalog No.:BCC2454
CAS No.:90417-38-2
- Daturataturin A aglycone
Catalog No.:BCN4445
CAS No.:904665-71-0
- Daturametelin I
Catalog No.:BCN4446
CAS No.:904667-65-8
- Maoyerabdosin
Catalog No.:BCN3944
CAS No.:90468-72-7
- Valeriotetrate C
Catalog No.:BCN6753
CAS No.:904891-20-9
- Cryptochlorogenic acid
Catalog No.:BCN5907
CAS No.:905-99-7
Genotoxicity of a variety of pyrrolizidine alkaloids in the hepatocyte primary culture-DNA repair test using rat, mouse, and hamster hepatocytes.[Pubmed:4005849]
Cancer Res. 1985 Jul;45(7):3125-9.
Seventeen pyrrolizidine alkaloids were studied with the hepatocyte primary culture-DNA repair test using rat hepatocytes. DNA repair synthesis was elicited by 15 alkaloids, including 11 of unknown carcinogenicity, i.e., senecionine, seneciphylline, jacobine, epoxyseneciphylline, senecicannabine, acetylfukinotoxin, syneilesine, dihydroclivorine, ligularidine, neoligularidine, and ligularizine. The positive results with these alkaloids of unknown carcinogenicity suggest that they are possibly genotoxic carcinogens. The two pyrrolizidine alkaloids that did not elicit DNA repair were retronecine which lacks a necic acid component and Ligularinine which lacks the unsaturated double bond at the 1,2-position of the pyrrolizidine ring. Five pyrrolizidine alkaloids, retronecine, monocrotaline, seneciphylline, senkirkine, and clivorine, were also tested in the DNA repair test with hamster or mouse hepatocytes. These alkaloids, except retronecine, showed a positive response in the test with hamster hepatocytes, but in the test with mouse hepatocytes clivorine in addition to retronecine was also negative. The results indicate a species difference in liver bioactivation of pyrrolizidine alkaloids, implying that there could be species differences in their carcinogenic activities.